A New Application For Alogliptin / ACTOS (pioglitazone HCl)
Alogliptin (SYR-322) drug is considered to be a member of the DPP-4 inhibitors class, which are newer oral agents for the treating diabetes (type 2 diabetes). The drug was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. By the way, Takeda is also the author of the thiazolidinedione (TZD) diabetes medication. The aim [...]
Read User's Comments